Hong Kong Stock Movement | CLOUDBREAK-B (02592) Surges Over 9% Intraday as Largest Single Shareholder Vows to Extend Lock-up Period by Six Months

Stock News2025-12-31

CLOUDBREAK-B (02592) surged more than 9% during the trading session, and as of the time of writing, the stock was up 5.17% to HK$5.29, with a turnover of HK$15.25 million. On the news front, CLOUDBREAK announced that its largest single shareholder, Water Lily, has voluntarily committed to extending the lock-up period for its shares in the company. The extension will commence the day after the original lock-up expiration date (January 3, 2026) and run until July 2, 2026, or an earlier date mutually agreed upon by both parties. Currently, Water Lily holds a total of 157 million shares, representing 18.71% of the company's total share capital. Furthermore, CLOUDBREAK recently issued an announcement stating that its wholly-owned subsidiary, ADS Therapeutics LLC, has submitted a clinical trial application to the FDA for its new presbyopia drug, CBT-199. This drug is a topical ophthalmic emulsion based on a proprietary water-insoluble platform, featuring high stability and a multi-dose design, and aims to improve near vision through miosis.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120732671?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-31 10:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120732671","market":"us","top_or_hot":-1,"title":"Hong Kong Stock Movement | CLOUDBREAK-B (02592) Surges Over 9% Intraday as Largest Single Shareholder Vows to Extend Lock-up Period by Six Months","media":"Stock News","content":"<p>CLOUDBREAK-B (02592) surged more than 9% during the trading session, and as of the time of writing, the stock was up 5.17% to HK$5.29, with a turnover of HK$15.25 million.\nOn the news front, CLOUDBREAK announced that its largest single shareholder, Water Lily, has voluntarily committed to extending the lock-up period for its shares in the company.\nThe extension will commence the day after the original lock-up expiration date (January 3, 2026) and run until July 2, 2026, or an earlier date mutually agreed upon by both parties.\nCurrently, Water Lily holds a total of 157 million shares, representing 18.71% of the company's total share capital.\nFurthermore, CLOUDBREAK recently issued an announcement stating that its wholly-owned subsidiary, ADS Therapeutics LLC, has submitted a clinical trial application to the FDA for its new presbyopia drug, CBT-199.\nThis drug is a topical ophthalmic emulsion based on a proprietary water-insoluble platform, featuring high stability and a multi-dose design, and aims to improve near vision through miosis.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Movement | CLOUDBREAK-B (02592) Surges Over 9% Intraday as Largest Single Shareholder Vows to Extend Lock-up Period by Six Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Movement | CLOUDBREAK-B (02592) Surges Over 9% Intraday as Largest Single Shareholder Vows to Extend Lock-up Period by Six Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-31 10:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CLOUDBREAK-B (02592) surged more than 9% during the trading session, and as of the time of writing, the stock was up 5.17% to HK$5.29, with a turnover of HK$15.25 million.\nOn the news front, CLOUDBREAK announced that its largest single shareholder, Water Lily, has voluntarily committed to extending the lock-up period for its shares in the company.\nThe extension will commence the day after the original lock-up expiration date (January 3, 2026) and run until July 2, 2026, or an earlier date mutually agreed upon by both parties.\nCurrently, Water Lily holds a total of 157 million shares, representing 18.71% of the company's total share capital.\nFurthermore, CLOUDBREAK recently issued an announcement stating that its wholly-owned subsidiary, ADS Therapeutics LLC, has submitted a clinical trial application to the FDA for its new presbyopia drug, CBT-199.\nThis drug is a topical ophthalmic emulsion based on a proprietary water-insoluble platform, featuring high stability and a multi-dose design, and aims to improve near vision through miosis.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02592","symbol_name":"拨康视云-B","start_time":0,"source_url":"","article_id":"1120732671","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120732671","pubTimestamp":1767148580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CLOUDBREAK-B (02592) surged more than 9% during the trading session, and as of the time of writing, the stock was up 5.17% to HK$5.29, with a turnover of HK$15.25 million. On the news front,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02592":"拨康视云-B","BK1161":"生物科技"},"translate_title":"港股动向|云破-B(02592)盘中大涨超9%最大单一股东誓言延长禁售期六个月","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02592":1},"content_text":"CLOUDBREAK-B (02592) surged more than 9% during the trading session, and as of the time of writing, the stock was up 5.17% to HK$5.29, with a turnover of HK$15.25 million.\nOn the news front, CLOUDBREAK announced that its largest single shareholder, Water Lily, has voluntarily committed to extending the lock-up period for its shares in the company.\nThe extension will commence the day after the original lock-up expiration date (January 3, 2026) and run until July 2, 2026, or an earlier date mutually agreed upon by both parties.\nCurrently, Water Lily holds a total of 157 million shares, representing 18.71% of the company's total share capital.\nFurthermore, CLOUDBREAK recently issued an announcement stating that its wholly-owned subsidiary, ADS Therapeutics LLC, has submitted a clinical trial application to the FDA for its new presbyopia drug, CBT-199.\nThis drug is a topical ophthalmic emulsion based on a proprietary water-insoluble platform, featuring high stability and a multi-dose design, and aims to improve near vision through miosis.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120732671","isCrawlerRequest":true}